A detailed history of Ubs Group Ag transactions in Argenx Se stock. As of the latest transaction made, Ubs Group Ag holds 1,917 shares of ARGX stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,917
Previous 2,208 13.18%
Holding current value
$1.08 Million
Previous $949,000 9.48%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $126,358 - $160,602
-291 Reduced 13.18%
1,917 $1.04 Million
Q2 2024

Aug 13, 2024

SELL
$356.01 - $451.55 $309,728 - $392,848
-870 Reduced 28.27%
2,208 $949,000
Q1 2024

May 13, 2024

BUY
$356.95 - $413.29 $507,225 - $587,285
1,421 Added 85.76%
3,078 $1.21 Million
Q4 2023

Feb 09, 2024

SELL
$338.91 - $506.01 $19,317 - $28,842
-57 Reduced 3.33%
1,657 $630,000
Q3 2023

Nov 09, 2023

SELL
$369.35 - $548.43 $113,390 - $168,368
-307 Reduced 15.19%
1,714 $842,000
Q2 2023

Aug 11, 2023

BUY
$360.14 - $422.58 $175,748 - $206,219
488 Added 31.83%
2,021 $787,000
Q1 2023

May 12, 2023

SELL
$334.23 - $403.65 $785,440 - $948,577
-2,350 Reduced 60.52%
1,533 $571,000
Q4 2022

Feb 08, 2023

BUY
$342.17 - $402.31 $678,865 - $798,183
1,984 Added 104.48%
3,883 $1.47 Million
Q3 2022

Nov 10, 2022

SELL
$343.2 - $395.75 $1.18 Million - $1.36 Million
-3,430 Reduced 64.36%
1,899 $671,000
Q2 2022

Aug 10, 2022

BUY
$269.58 - $378.88 $38,010 - $53,422
141 Added 2.72%
5,329 $2.02 Million
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $748,591 - $1.03 Million
-2,942 Reduced 36.19%
5,188 $1.64 Million
Q4 2021

Feb 14, 2022

SELL
$272.01 - $353.03 $1.19 Million - $1.55 Million
-4,381 Reduced 35.02%
8,130 $2.85 Million
Q3 2021

Nov 15, 2021

BUY
$295.0 - $350.58 $1.03 Million - $1.23 Million
3,501 Added 38.86%
12,511 $3.78 Million
Q2 2021

Aug 13, 2021

BUY
$257.11 - $319.92 $920,968 - $1.15 Million
3,582 Added 65.99%
9,010 $2.71 Million
Q1 2021

May 12, 2021

BUY
$268.3 - $380.31 $888,341 - $1.26 Million
3,311 Added 156.4%
5,428 $1.5 Million
Q4 2020

Feb 11, 2021

BUY
$248.13 - $308.36 $21,835 - $27,135
88 Added 4.34%
2,117 $623,000
Q3 2020

Nov 12, 2020

SELL
$215.51 - $272.51 $55,817 - $70,580
-259 Reduced 11.32%
2,029 $533,000
Q2 2020

Jul 31, 2020

SELL
$127.44 - $232.72 $53,397 - $97,509
-419 Reduced 15.48%
2,288 $515,000
Q1 2020

May 01, 2020

BUY
$108.83 - $165.23 $121,889 - $185,057
1,120 Added 70.57%
2,707 $357,000
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $131,105 - $201,978
-1,230 Reduced 43.66%
1,587 $255,000
Q3 2019

Nov 14, 2019

SELL
$113.31 - $150.51 $1.05 Million - $1.39 Million
-9,225 Reduced 76.61%
2,817 $321,000
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $1.01 Million - $1.25 Million
8,821 Added 273.86%
12,042 $1.71 Million
Q1 2019

May 14, 2019

BUY
$98.85 - $134.59 $10,774 - $14,670
109 Added 3.5%
3,221 $402,000
Q4 2018

Feb 14, 2019

SELL
$63.81 - $109.82 $7,593 - $13,068
-119 Reduced 3.68%
3,112 $299,000
Q3 2018

Nov 14, 2018

BUY
$75.5 - $96.63 $180,143 - $230,559
2,386 Added 282.37%
3,231 $245,000
Q2 2018

Aug 14, 2018

BUY
$74.84 - $100.16 $10,552 - $14,122
141 Added 20.03%
845 $70,000
Q1 2018

May 15, 2018

SELL
$56.95 - $85.19 $40,092 - $59,973
-704 Reduced 50.0%
704 $57,000
Q4 2017

Feb 14, 2018

BUY
$22.57 - $63.56 $31,778 - $89,492
1,408
1,408 $89,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.